Medicine and Dentistry
Neoplasm
81%
Positron Emission Tomography
41%
Malignant Neoplasm
41%
Prostate Specific Membrane Antigen
32%
Programmed Death 1 Ligand 1
29%
Imaging Agent
25%
Fluorine-18
24%
Radioactive Tracer
22%
Tumor Xenograft
20%
Metastatic Carcinoma
19%
Single-Photon Emission Computed Tomography
17%
Cancer Cell
17%
Prostate Cancer
17%
Molecular Imaging
15%
Gallium 68
14%
Chemokine Receptor
13%
Programmed Death-Ligand 1
12%
Single Photon Emission Computed Tomography-Computed Tomography
11%
Immunotherapy
11%
Copper 64
11%
Positron Emission Tomography
11%
Biodistribution
11%
Cancer Immunotherapy
10%
Hypoxia
9%
Ovarian Cancer
9%
Thymidine Kinase
9%
Oncology
9%
Positron Emission Tomography-Computed Tomography
9%
Lung Cancer
8%
Triple Negative Breast Cancer
8%
In Vitro
8%
Cancer Therapy
8%
Optical Imaging
8%
Combination Therapy
7%
Fialuridine
7%
Fluorodeoxyglucose F 18
7%
Solid Malignant Neoplasm
6%
Diagnosis
6%
Magnetic Resonance Imaging
6%
Tumor Progression
6%
Downregulation
6%
Positron Emission Tomography - Magnetic Resonance Imaging
6%
Chemokine
6%
Monoclonal Antibody
6%
Antigen Expression
5%
Pharmacodynamics
5%
Tetraxetan
5%
Nanoparticle
5%
Pyridine
5%
Cell Membrane
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
55%
Prostate Specific Membrane Antigen
42%
Programmed Death 1 Ligand 1
38%
Fluorine 18
36%
Prostate Cancer
27%
Tracer
24%
Mouse
21%
Biodistribution
18%
Copper 64
18%
Gallium 68
18%
Chemokine Receptor
17%
Nanoparticle
15%
Pharmacokinetics
14%
Iodine-125
14%
Pharmacodynamics
12%
Indium 111
11%
Thymidine Kinase
10%
Dosimetry
10%
Carbonate Dehydratase IX
9%
Dendrimer
9%
Fialuridine
9%
Pentobarbital
7%
Combination Therapy
7%
Glutaric Acid
7%
Chemokine
7%
N [1,4,8,11 Tetraazacyclotetradecanyl 1,4 Phenylenebis(methylene)] 2 (Aminomethyl)pyridine
7%
Monoclonal Antibody
6%
Solid Malignant Neoplasm
6%
Non Small Cell Lung Cancer
6%
Triple Negative Breast Cancer
6%
Immunotherapy
5%
Tumor Growth
5%
Poly(amidoamine)
5%
Tetraxetan
5%
Pyridine
5%
Brain Tumor
5%
Choline Kinase
5%
Chelating Agent
5%
Chemokine Receptor CXCR4
5%
Radioligand
5%
Immune Checkpoint Inhibitor
5%
Iodine 124
5%
Keyphrases
Programmed Death-ligand 1 (PD-L1)
63%
Tumor
60%
Positron Emission Tomography
37%
C-X-C Chemokine Receptor Type 4 (CXCR4)
24%
Prostate-specific Antigen
23%
Gallium-68
20%
Programmed Death-ligand 1 Expression
18%
In Cancer
18%
Radiotracer
17%
Imaging Agents
15%
Tumor Xenograft
15%
Prostate Cancer
15%
Targeted Theranostics
14%
Positron Emission Tomography-computed Tomography (PET-CT)
11%
Hypoxia
10%
124I
9%
Bacterial Infection
9%
Ovarian Cancer
9%
Molecular Imaging
9%
Peptide-based
8%
Pharmacodynamics
8%
Metastasis
8%
125I
8%
Colon Tissue
7%
Theranostic Agent
7%
Chemokine Ligand 12 (CXCL12)
7%
SPECT Imaging
7%
Triple-negative Breast Cancer
7%
Optical Imaging
6%
Musculoskeletal Infection
6%
Non-invasive Imaging
6%
Antigen Expression
6%
Chemical Exchange Saturation Transfer Imaging
6%
Solid Tumors
5%
Cancer Immunotherapy
5%
Polyamidoamine (PAMAM)
5%
Pharmacokinetics
5%
Immune Checkpoint Therapy
5%
Cancer Xenograft
5%
PET Radiotracers
5%
Biodistribution Studies
5%
Role in Cancer
5%
Choline Kinase
5%
Dendrimer
5%
CXCR4 Expression
5%
Cancer Imaging
5%
Therapeutic Efficacy
5%
